Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

First US implant of the DuraHeart Left Ventricular Assist System takes place

Terumo Heart : 07 August, 2008  (Company News)
Terumo Heart has announced that the first US implant of the DuraHeart Left Ventricular Assist System (LVAS) took place on July 30, 2008 at the University of Michigan Cardiovascular Center in Ann Arbor, Michigan, USA.
The surgery was performed by Francis Pagani, MD, PhD national co-principal investigator for the DuraHeart US Pivotal Trial. DuraHeart is the world's first third generation left ventricular assist system combining a centrifugal pump with a magnetically levitated impeller to enter clinical trials in the USA.

'The DuraHeart gives us a new, third-generation option for patients with advanced heart failure who need help to allow them to survive until they can receive a heart transplant,' said Pagani, who leads the U-M Center for Circulatory Support.

Chisato Nojiri, MD, PhD, chief executive officer for Terumo Heart, said, 'The first patient in the United States is an important initial step in the pivotal trial. This patient is the 71st patient worldwide since the DuraHeart European investigational trials began in 2004. We have had exceptional outcomes in Europe and look forward to similar outcomes in the US.'

In clinical results as of July 31, 2008, patient support averaged 223 days with cumulative support of 43 years. The longest ongoing patient support is over three years.

The DuraHeart LVAS Pivotal Trial is a multi-centre, prospective, non-randomized study of 140 patients and will include up to 40 centres. The device is intended to provide cardiac support for patients awaiting transplant who are at risk of death due to end-stage left ventricular heart failure. Yoshifumi Naka, MD, PhD, from Columbia Presbyterian Hospital in New York, will serve as the national co-principal investigator with Dr Pagani.

Dr Nojiri added, 'We are excited at the prospect of making this state of the art technology readily available for the increasing need of heart failure patients. Third generation systems are anticipated to demonstrate improved outcomes and long term reliability. DuraHeart is the most advanced third generation centrifugal pump by virtue of the magnetically levitated impeller, positioning us for a leadership role in the future treatment of heart failure.'

In addition to the US trial, Terumo Heart is expected to initiate clinical trials in Japan this year.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo